CLevel Interviews Confirm Allogene (ALLO) Best Positioned Among Next Gen Cell Therapies - Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NASDAQ: ALLO) | Delayed: 1.25 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.25 | 52 Week High | $ | |||
| Open | $1.23 | 52 Week Low | $ | |||
| Day High | $1.26 | P/E | N/A | |||
| Day Low | $1.16 | EPS | $ | |||
| Volume | 8,404,825 | |||||
